Response to treatment and adverse events associated with use of recombinant activated factor VII in children: a retrospective cohort study
{{output}}
Background: Recombinant activated factor VII (rFVIIa) is United States (US) Food and Drug Administration (FDA)-approved for patients with hemophilia with inhibitors or congenital factor VII deficiency. Initial reports of off-labe... ...
